Complete Rescue of Lethal Albino c Mice by Null Mutation of 4-Hydroxyphenylpyruvate Dioxygenase and Induction of Apoptosis of Hepatocytes in These Mice by in VivoRetrieval of the Tyrosine Catabolic Pathway-Reference-Cited by-同舟云学术

Complete Rescue of Lethal Albino c Mice by Null Mutation of 4-Hydroxyphenylpyruvate Dioxygenase and Induction of Apoptosis of Hepatocytes in These Mice by in VivoRetrieval of the Tyrosine Catabolic Pathway

Published:1997-09 Issue:39 Volume:272 Page:24426-24432
ISSN:0021-9258
Container-title:Journal of Biological Chemistry
language:en
Short-container-title:Journal of Biological Chemistry

Author:

Endo Fumio,Kubo Shuji,Awata Hisataka,Kiwaki Koji,Katoh Hideki,Kanegae Yumi,Saito Izumu,Miyazaki Jun-ichi,Yamamoto Tetsuro,Jakobs Cornelis,Hattori Shinzaburo,Matsuda Ichiro

Publisher

Elsevier BV

Subject

Cell Biology,Molecular Biology,Biochemistry

Reference36 articles.

1. The Metabolic and Molecular Bases of Inherited Disease;Mitchell,1995

2. Type 1 hereditary tyrosinemia. Evidence for molecular heterogeneity and identification of a causal mutation in a French Canadian patient.

3. Treatment of hereditary tyrosinaemia type I by inhibition of 4-hydroxyphenylpyruvate dioxygenase

4. Genetic control of morphogenetic and biochemical differentiation: Lethal albino deletions in the mouse

Cited by 56 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. In vivo dissection of the mouse tyrosine catabolic pathway with CRISPR-Cas9 identifies modifier genes affecting hereditary tyrosinemia type 1;GENETICS;2024-08-23

2. Ex vivo gene editing and cell therapy for hereditary tyrosinemia type 1;Hepatology Communications;2024-04-26

3. In vivodissection of the mouse tyrosine catabolic pathway with CRISPR-Cas9 identifies modifier genes affecting hereditary tyrosinemia type 1;2023-09-29

4. In vivo treatment of tyrosinaemia with hypercompact Cas12f1;Cell Discovery;2023-07-18

5. Genetically blocking HPD via CRISPR-Cas9 protects against lethal liver injury in a pig model of tyrosinemia type I;Molecular Therapy - Methods & Clinical Development;2021-06